Condition (MeSH)
Genomic Instability
ClinicalTrials.gov lists 66 trials for Genomic Instability or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
9 of the 66 trials are tagged with Genomic Instability itself; the rest are tagged with a narrower condition beneath it.
When did Genomic Instability trials start? (18)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 3 |
| 2024 | 4 |
| 2023 | 9 |
| 2022 | 5 |
| 2021 | 3 |
| 2019 | 10 |
| 2018 | 10 |
| 2017 | 8 |
| 2016 | 1 |
Showing 10 of 18 earlier years.
No forecast is made for this condition: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 9 trials still running at the 2026-10-09 snapshot; registered median of 47 months across 28 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Genomic Instability trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 5 |
| Phase 2 | 15 |
| Phase 3 | 2 |
| Phase 4 | 1 |
| Not applicable | 6 |
| Observational | 31 |
How many Genomic Instability trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 9 |
| Active, not recruiting | 9 |
| Completed | 21 |
| Terminated | 4 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Genomic Instability trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Fate Therapeutics | 2 |
| Volastra Therapeutics, Inc. | 2 |
| Accent Therapeutics | 1 |
| Apollomics (Australia) Pty. Ltd. | 1 |
Which drugs are being tested for Genomic Instability? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| PEMBROLIZUMAB | 5 |
| NIVOLUMAB | 3 |
| DURVALUMAB | 2 |
| IPILIMUMAB | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Atezolizumab SC | 2 |
| Nivolumab 10 MG/ML | 2 |
| AG chemotherapy | 1 |
| N-803 + Avelumab + PD-L1 t-haNK | 1 |
| FT500 | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Genomic Instability trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Malignant neoplasm progression | 70 | 1 |
| Pneumonia | 32 | 1 |
| Abdominal pain | 28 | 1 |
| Nausea | 26 | 1 |
| Pleural effusion | 25 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Genomic Instability? (109)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib. | Genome medicine | 2024 | Yes |
| Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. | Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc | 2021 | Yes |
| Role of Nicotinamide in Genomic Stability and Skin Cancer Chemoprevention. | International journal of molecular sciences | 2019 | Yes |
| Impact of obesity and overweight on DNA stability: Few facts and many hypotheses. | Mutation research. Reviews in mutation research | 2018 | Yes |
| Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications. | Stem cell reviews and reports | 2017 | Yes |
Showing 5 of 109 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.